Parkinson’s disease (PD) is the second most common chronic neurodegenerative disease in the elderly population. The motor symptoms that characterize PD are bradykinesia, tremor, rigidity, and postural instability, together with non-motor symptoms such as depression, anxiety, sleep disorders and cognitive dysfunction. These symptoms lead to severe impairment of the quality of life for the PD patient (Frucht, 2004). Pathological analyses of post-mortem brains have shown Lewy bodies, which are abnormal protein aggregates found within nerve cells, and a progressive loss of substantia nigra dopamine neurons (Iacono et al., 2015). Among the molecular mechanisms suggested to cause PD are cellular oxidative stress and autophagy. Pesticide exposure, use of well water, heavy metal exposure, and industrialization are some of the environmental factors that contribute to the development of PD (Willis et al., 2010a,b).

Over recent years, extensive genetic screening of PD families has aimed at identifying mutations associated with the disease that would give a deeper insight into the molecular mechanisms underlying the PD pathology. Genetic studies identified several genomic risk loci associated with familial PD, such as PARK1-15 and other related genes (Masliah et al., 2000; Cheon et al., 2012). Additionally, other genes, including LRRK2, SNCA, MAPT, and GBA, have been associated with sporadic PD (Coppede, 2012). Even though there is evidence that PD can be caused sporadically by familial genetic mutations (causal mutations), such as in alpha-synuclein (SNCA) or Parkin, it is more likely that in most patients the disease develops as a consequence of the combination of mutations in multiple PD-associated genes and environmental risk factors.

In addition to the genetic component involved in the development of many disorders (acquired mutations in one gene or a group of genes), epigenetic mechanisms have been found to contribute significantly to their development. Epigenetic factors are chemical modifications of chromatin or its regulatory proteins that do not change the underlying genomic sequence. These modifications can modulate gene expression, allowing differentiation into different cellular phenotypes by driving tissue-specific expression patterns. These changes include DNA methylation, post-translational modifications of histones, chromatin remodeling, as well as small and long non-coding RNAs (Turner, 2007).

Epigenetic regulation of biological processes is known to be essential during embryonic development, early brain programming, neurogenesis and brain plasticity (Yao et al., 2016). Therefore, it is not surprising that epigenetic deregulation can be critical for the onset of various neurodegenerative diseases, such as PD (Ammal Kaidery et al., 2013). Previously, a comprehensive genomic study identified several PD risk loci in cerebellum and frontal cortex of PD brains, including PARK16, GPNMB, and STX1B genes, that were associated with differential DNA methylation at proximal CpG sites (International Parkinson’s Disease Genomics Consortium (IPDGC) and Wellcome Trust Case Control Consortium 2 (WTCCC2), 2011).

Importantly, as there is currently no animal model that mimics PD; human brain is still the model used to study epigenetic changes. However, as PD brain tissue is predominantly analyzed post-mortem, this data cannot provide information about disease-progressive alterations, the extent of variations induced by previous therapeutic treatments and the occurrence of potential PD biomarkers. Access to brain samples for research is limited, so the focus has been on finding a more easily accessible tissue, such as peripheral blood, as a surrogate for brain tissue. For this purpose, a genome-wide study examined DNA methylation changes in PD patients by collecting fresh post-mortem brain and blood samples from PD patients and age-matched healthy subjects (Masliah et al., 2013). This comparison revealed that both tissues exhibited highly similar global DNA methylation patterns. Accordingly, Masliah et al. (2013) identified groups of genes with either increased or decreased DNA methylation in both PD brain and blood samples. Importantly, analysis of DNA methylation profiles of blood clearly distinguishes PD patients from healthy subjects or subjects with other disorders. These results suggest that, firstly, peripheral blood may be a valid surrogate for brain tissue samples, and secondly, epigenetic changes could potentially serve as biomarkers for the diagnosis of PD. Early biomarkers could improve the prognosis of PD by facilitating the initiation of rational treatment before significant neurological damage takes place. Here, we discuss the current evidence for DNA methylation changes in PD, including the involvement of nutrition and environmental factors.

DNA methylation is the most studied epigenetic modification, one that has been investigated in almost all pathologies. In mammals, DNA methylation takes place predominantly in the context of CpG dinucleotides (Ehrlich and Wang, 1981). While overall the genome is widely depleted of CpGs, CpG islands are regions of high CpG content (Takai and Jones, 2002; Wu et al., 2010). CpG islands are characteristic for more than 60% of all promoters of protein-coding genes. Whereas on a genome-wide level up to 70–80% of all CpG sites are methylated, CpG islands are mostly devoid of DNA methylation (Bird, 2002; Edwards et al., 2010). Adjacent to a CpG island, 2 kilo base pairs (kb) up- and down-stream, are its so-called CpG shores (Irizarry et al., 2009). The presence of DNA methylation, at least at gene promoters and regions of repetitive sequences, is linked to chromatin silencing (Hsieh, 1994; Siegfried et al., 1999). Two principal mechanisms, which are not mutually exclusive, are thought to explain the repressive effect of DNA methylation on gene repression (Bird and Wolffe, 1999; Klose and Bird, 2006). First: DNA methylation interferes with the recognition of transcription factor (TF) binding sites and thereby impairs gene activation (Domcke et al., 2015). Second: DNA methylation is recognized by specific Methyl-CpG binding proteins, such as MeCP2, that recruit co-repressor protein complexes and thereby mediate silencing (Nan et al., 1998). Aberrant methylation patterns at CpG islands and shores have been linked to human disease, including multiple cancers (Ohm et al., 2007; Irizarry et al., 2009; Berman et al., 2011; Manjegowda et al., 2017).

In developing embryos and germ cells, DNA methylation patterns are first established by de novo DNA methyltransferases (DNMTs), DNMT3A and DNMT3B. After this, DNA methylation is maintained during DNA replication by DNMT1, which localizes to the replication fork during S-phase where it binds to hemimethylated CpGs (Jones and Liang, 2009; Jung et al., 2017). In 2009, ten-eleven translocation (TET) enzymes were identified that can reverse DNA methylation, by oxidization of 5-methyl cytosine (5mC) to 5-hydroxymethyl cytosine (5hmC) (Tahiliani et al., 2009; Pastor et al., 2013). 5hmC can be lost passively by dilution during replication or be actively removed by subsequent oxidative reactions catalyzed by TET proteins that result in the formation of 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) as intermediates (Ito et al., 2011). Finally, the thymine DNA glycosylase (TDG)-mediated base excision repair (BER) replaces the methylated site by an unmodified cytosine (He et al., 2011; Kohli and Zhang, 2013).

Importantly, it appears that the 5hmC modification is not only an intermediate of 5mC demethylation, but has been considered to be an epigenetic mark in itself. Although the exact role of 5hmC is still being studied intensively, it seems to have a distinct function from that of 5mC. Particularly in neuronal cells, DNA hydroxymethylation was found to be enriched in gene bodies of actively transcribed genes (Mellen et al., 2012; Hahn et al., 2013). Given the relative abundance of DNA hydroxymethylation in the brain and its apparent role in normal brain maturation and memory formation (Szulwach et al., 2011; Kaas et al., 2013; Lister et al., 2013; Kinde et al., 2015), it has been implicated in the onset and progression of several neurodegenerative disorders (Villar-Menendez et al., 2013; Wang et al., 2013; Condliffe et al., 2014; Coppieters et al., 2014). Although not as widespread as 5mC and 5hmC, there is emerging evidence that cytosine methylation also exists outside of the sequence context of CpG sites (non-CpG methylation: CpA, CpT, and CpC) and appears to be most common in embryonic stem cells (Lister et al., 2009) and adult brain tissue (Varley et al., 2013; Guo et al., 2014). Non-CpG methylation occurs postnatally during the primary phase of neuronal maturation and may play a role in transcriptional repression (Lister et al., 2013; Guo et al., 2014). However, as it is technically challenging to target this modification in vivo without altering CpG methylation in the process, extensive research is still required to elucidate the distinct biological function of non-CpG methylation.

Genetically, aging is characterized by distinct alterations that take place at the chromatin level. These include telomere shortening, increased genome instability and changes of epigenetic signatures, such as DNA methylation patterns (Lopez-Otin et al., 2013). Age-related remodeling of DNA methylation comprises events of both hypo- and hypermethylation (Maegawa et al., 2010; Jung and Pfeifer, 2015). DNA hypomethylation happens globally at CpG sites outside of CpG islands (Christensen et al., 2009; Heyn et al., 2012; Day et al., 2013), while DNA hypermethylation affects mostly CpG islands in promoters of genes, which are frequently involved in development and differentiation (Christensen et al., 2009; Rakyan et al., 2010). Therefore, over time the accumulation of epimutations, which are heritable changes of gene activity mediated by epigenetic alterations, are believed to contribute to genomic instability just as genetic mutations do.

Interestingly, the methylation states at specific CpG loci can be consulted as epigenetic biomarkers to reliably predict the human chronological age (Horvath, 2013; Weidner et al., 2014). Moreover, twin studies determined that in each human, the age-dependent aggregation of distinct epigenetic changes, termed ‘epigenetic drift,’ is thought to be influenced predominantly by environmental factors (Fraga et al., 2005; Tan Q. et al., 2016). The individual differences in exposure to these factors are suspected to contribute to variation in disease susceptibility, onset, progression, etiopathology, treatment response and disease outcome. Taken together, changes in DNA methylation patterns and their effects on chromatin and gene expression appear to add increasingly to our understanding of age-related diseases, including PD. In the following, we will summarize and discuss the current evidence of DNA methylation changes at candidate genes that could be related to the development of PD.

The SNCAp.Ala53Thr mutation, described in 1997, was the first genetic cause of PD identified (Polymeropoulos et al., 1997). This missense mutation provided the first link between SNCA and familial PD after its identification in a family from Southern Italy. The respective gene product, the SNCA protein, was discovered almost simultaneously (Spillantini et al., 1997). At the molecular level, SNCA aggregation contributes majorly to the formation of Lewy bodies, a hallmark of PD pathology. In addition to genetic mutations, also SNCA locus amplifications (duplications, triplications) have been found as a cause of familial PD (Singleton et al., 2003; Chartier-Harlin et al., 2004). SNCA point mutations, as well as gene multiplications and overexpression, are all thought to play a causal role in the formation of Lewy bodies (Narhi et al., 1999; Masliah et al., 2000). That SNCA gene dosage is critical for the development of PD, was further supported by mouse models with neuronal expression of wild-type SNCA (Masliah et al., 2000; Janezic et al., 2013). These transgenic mice revealed PD-like loss of dopaminergic neurons, protein aggregate formation, and motor impairments.

As gene dosage can be changed not only by gene amplification, but also by gene regulation, DNA methylation was considered as a potential mechanism that could be involved in the deregulation of SNCA in the case of PD. Accordingly, sequence analysis of the promoter region of the SNCA gene led to the identification of two CpG islands (Matsumoto et al., 2010). The first, CpG-1 is located in the first exon but does not overlap with the coding region of SNCA, and the second, CpG-2 is located in the first intron. In luciferase reporter assays the promoter activity of sequences containing CpG-2 was indeed strongly reduced by in vitro DNA methylation prior to cell transfection (Jowaed et al., 2010; Matsumoto et al., 2010). Furthermore, treatment of SK-N-SH cells with a DNA methylation inhibitor resulted in a reduction of CpG-2 methylation and a significant increase of SNCA mRNA and protein levels (Jowaed et al., 2010). These data supported the idea that DNA methylation at least at the intronic CpG-2 island could control SNCA gene activity. In fact, several studies analyzing the DNA methylation levels in samples of PD patients compared to controls confirmed a hypomethylation of intron 1 that coincides with the second SNCA CpG island. Using brain samples a significant demethylation of intron 1 was reported in the substantia nigra pars compacta (SnPC) of PD patients which could explain increased SNCA expression (Jowaed et al., 2010; Matsumoto et al., 2010). Taking into account the observation that DNA methylation patterns between blood and brain tissue show a strong correlation (Masliah et al., 2013), more recent studies analyzed peripheral blood samples of PD subjects instead of or in addition to post-mortem brain tissue. In agreement with the assumption that DNA methylation profiles in the brain could be potentially mirrored in blood cells, a recent study found SNCA promoter hypomethylation in both post-mortem cortex and peripheral blood samples (Pihlstrom et al., 2015). Another study reported hypomethylation of SNCA intron 1 in peripheral blood mononuclear cells of 100 sporadic PD subjects (Ai et al., 2014). In 2015, the largest study carried out to date analyzing 490 peripheral blood samples of patients with sporadic PD, also revealed hypomethylation of SNCA intron 1. In contrast, SNCA methylation was found to be increased in PD patients who received higher L-dopa dosage. Accordingly, L-dopa led to a specific increment of DNA methylation of SNCA intron 1 in mononuclear cell cultures. Interestingly, the detection of DNMT1 in post-mortem brain tissue of PD patients and in SNCA transgenic mice uncovered that the amount of enzyme was strongly reduced in the nuclear fraction of neuronal cells (Desplats et al., 2011). Thus, sequestration of DNMT1 in the cytosol could explain the global, as well as the SNCA gene-specific, PD-dependent DNA hypomethylation, mechanistically.

In recent years, meta-analyses of genome-wide association studies (GWAS) on single nucleotide polymorphism (SNP) data of large PD case-control cohorts were conducted (Nalls et al., 2011, 2014; Sharma et al., 2012). These studies identified risk loci in both genes, previously not linked to PD pathology, and known key players, such as SNCA. Thereby, obtained results substantiated that there is a major genetic component contributing to the susceptibility to PD. But additionally, inter-individual genetic variants can frequently be associated with DNA methylation differences at distinct CpG sites and are defined in statistical analyses as methylation quantitative trait loci (mQTLs). Two recent studies investigated the relationship between genetic variation and CpG methylation in the human brain (Gibbs et al., 2010; Zhang et al., 2010). In case of the SNCA gene, three independent studies noted that the genotype SNP rs3756063 showed a significant correlation with the DNA methylation state of SNCA intron 1 both in brain and blood PD samples (Pihlstrom et al., 2015; Schmitt et al., 2015; Wei et al., 2016). However, it should be noted that an association between rs3756063 and the SNCA mRNA expression could not be found (Pihlstrom et al., 2015; Wei et al., 2016). Furthermore, another association could be established between the SNCA DNA methylation levels and the Rep1 polymorphism (Ai et al., 2014). In contrast to rs3756063, Rep1 is a complex microsatellite repeat polymorphism located approximately 10 kb upstream of the SNCA transcription start site (Figure 1). Its longest 263 bp allele has previously been associated with sporadic PD (Maraganore et al., 2006). In agreement with an elevated PD risk, genotypes carrying the 263 bp allele showed the strongest SNCA intron 1 hypomethylation (Ai et al., 2014). Experiments in transgenic mice suggested a cis-regulatory effect of the Rep1-length regulating SNCA transcription, whereby homozygosity of the expanded 263 bp allele correlated with the highest gene expression (Cronin et al., 2009). Controversially, recent data obtained by the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technique, to edit the genome Rep1 locus in human embryonic stem cell-derived neurons, contradict the enhancer function of the repeat sequence and do not detect a correlation between SNCA expression and Rep1-length (Soldner et al., 2016). Likewise, the interdependency between DNA methylation alterations in the SNCA locus and genetic variants, is not understood mechanistically, neither in case of Rep1 nor rs3756063. Genetic variation does not only impact DNA methylation, but also dictates differences in binding of TFs in individuals on a genome-wide level (Kasowski et al., 2010). Therefore, it will be a great challenge to unravel the molecular mechanisms behind these associations, as they are expected to be connected with each other in a complicated network.

Although the studies cited above suggest DNA hypomethylation of the SNCA promoter region in PD patients, discrepancies with other findings exist. For example, one study revealed variations of DNA methylation levels at the SNCA gene in different brain regions. Both hypomethylation, as well as hypermethylation, were detected in various Lewy body disease/PD stages in both the promoter region and intron 1 (de Boni et al., 2011). Another recent study found no intron 1 hypomethylation of SNCA in a limited number of PD patients (Guhathakurta et al., 2017). Moreover, the analysis of blood samples from 43 PD subjects provided no evidence for DNA methylation changes within the SNCA promoter region (Richter et al., 2012), just as another study comprising blood leukocyte samples of 50 PD patients (Song et al., 2014). However, it should be noted, that in the latter two studies (Richter et al., 2012; Song et al., 2014) 10 times less subjects participated compared to the analysis of Schmitt et al. (2015) that detected differential DNA methylation at the SNCA gene.

In light of the inconsistencies concerning the relevance of DNA hypomethylation at the SNCA intron 1 in association with PD, additional studies will be needed to resolve these doubts. Also, even if SNCA intron 1 hypomethylation can be consistently confirmed in PD, similar DNA patterns were also found in both Dementia with Lewy Bodies (DLB) (Funahashi et al., 2017) and AD (Yoshino et al., 2016). Therefore, it is conceivable that this DNA methylation change would not serve as a specific biomarker for PD, but a more general one for all Lewy body pathologies.

In the following section, we will give an overview of what is known so far about the epigenetic signatures of DNA methylation at genes that were found to be associated with the development of PD (compare Table 1).

Due to its relation to SNCA and its abundance in neurofibrillary lesions of patients with AD, the beta-synuclein (SNCB) gene has also been considered as a possible player in PD. Interestingly, SNCB inhibits the generation of SNCA fibril aggregation in vitro (Park et al., 2003) and therefore, may play a neuroprotective role (Vigneswara et al., 2013). Furthermore, SNCB and SNCA have similar expression levels in nervous system tissue samples (Maroteaux et al., 1988). Moreover, SNCA and SNCB associate in vitro whereby SNCB may protect SNCA from aging-related protein damage (Vigneswara et al., 2013). However, to date, the specific role SNCB plays in PD has not been elucidated. A DNA methylation study carried out in PD samples to examine the SNCB gene found its promoter to be unmethylated in post-mortem brain from PD and PD-Dementia samples. Additionally, bisulfite sequencing of the SNCB promoter in four pure diffuse Lewy body pathology cases did not reveal methylated cytosines along the CpG island (Beyer et al., 2010).

Post-translational citrullination (deimination) is mediated by peptidyl arginine aminases (PADs) and has been implicated as an unusual pathological trait in neurodegeneration and inflammatory responses in multiple sclerosis, AD and prion diseases (Jang et al., 2013). Alterations in the expression of these proteins have also been seen in post-mortem samples taken from different brain areas of PD subjects (Nicholas, 2011). In thymus samples from multiple sclerosis patients, the promoter of PAD2 (peptidyl arginine deaminase type II) was reported to be hypomethylated (Sokratous et al., 2016). In contrast, white matter from PD, AD, or Huntington disease patients showed that PAD2 was not hypomethylated (Mastronardi et al., 2007). DNA methylation analysis of the tumor necrosis factor alpha (TNF-alpha) gene, another PD-associated gene, showed a significantly lower methylation level comparing DNA from the SnPC to DNA from brain cortex. However, this difference could not be linked to PD as it was observed in both PD subjects and controls (Pieper et al., 2008). In another study, the UCHL1 promoter from post-mortem frontal cortex samples was analyzed, and no differences in the percentage of CpG methylation between PD cases and controls were found (Barrachina and Ferrer, 2009).

Behrens et al. analyzed the ATP13A2 promoter region from four PD subjects with Kufor-Rakeb syndrome, a rare Type 9 juvenile PD that is linked to a mutation in the ATP13A2 gene (Behrens et al., 2010). No significant correlation between DNA methylation changes of the hypomethylated promoter and Kufor-Rakeb syndrome juvenile PD progression was found. Another study considered the known association of Parkin (PARK2) gene mutations with autosomal recessive juvenile PD. Samples from 17 PD subjects with heterozygous Parkin mutations, as well as 17 PD subjects without Parkin mutations, were compared to samples from 10 normal subjects. No significant differences in DNA methylation at CpG sites among these three groups were found, suggesting that a DNA methylation-related mechanism involving the Parkin gene was unlikely to play a role in the pathogenesis and development of this type of PD (Cai et al., 2011). A recent study compared the DNA methylation status of the PARK2 promoter region in 5 post-mortem brain samples taken from substantia nigra, cerebellum, and occipital cortex (De Mena et al., 2013). In agreement, with previous results (Cai et al., 2011) no differential DNA methylation of PARK2 was seen (De Mena et al., 2013).

The expression of clock genes, which are components of the circadian clock, is altered in leukocytes from patients with PD (Cai et al., 2010). With this in mind, a study was recently carried out in which DNA methylation status of the clock genes PER1, PER2, CRY1, CRY2, Clock, NPAS2, and BMAL1 was measured in genomic DNA isolated from blood samples of 206 PD subjects. DNA methylation was detectable in CRY1 and NPAS2 promoters whereas the remaining gene promoters analyzed were devoid of DNA methylation. Interestingly, DNA methylation frequency of the NPAS2 promoter was significantly decreased in PD patients, suggesting that its promoter DNA methylation may contribute to the expression of clock genes in PD (Lin et al., 2012). This finding could be relevant, as sleep disturbance is a commonly reported early symptom of PD (Breen et al., 2014).

Another gene of interest for the analysis of epigenetic changes is the microtubule-associated protein tau (MAPT) gene, as a genetic association with PD has been noted in GWAS (Simon-Sanchez et al., 2009). When 28 post-mortem brain and 358 blood leukocyte samples were analyzed, higher DNA methylation in MAPT was detected in H1 haplotype versus H2 (Coupland et al., 2014). Notably, in previous studies the presence of the H1 haplotype was associated significantly with PD (Kwok et al., 2004; Zabetian et al., 2007; Refenes et al., 2009). Additionally, DNA hypermethylation of the MAPT gene was observed in the cerebellum, but not in putamen from PD subjects where the MAPT gene was hypomethylated as compared with controls (Coupland et al., 2014).

DNA hypermethylation of the peroxisome proliferator-activated receptor gamma coactivator-1 α (PGC-1α) promoter was reported in a sample of sporadic PD substantia nigra samples compared to 10 age-matched controls (Su et al., 2015). Recently, PARK7 (DJ-1) DNA methylation was analyzed in peripheral blood leukocytes in PD subjects and controls. In contrast to the hypermethylated PGC-1α promoter (Su et al., 2015), they found the CpG-1 and CpG-2 islands of PARK7 to be unmethylated in both PD and the negative control group (Tan Y. et al., 2016).

To detect further PD associated DNA methylation variations, an epigenome-wide association study was done to analyze DNA methylation patterns in putamen samples from post-mortem brain tissue of six PD patients. DNA methylation levels were quantitatively determined at 27,500 CpG sites representing 14,495 genes. This analysis revealed decreased DNA methylation at the cytochrome P450 2E1 (CYP2E1) gene, together with increased expression of the respective CYP2E1 messenger RNA, suggesting that this cytochrome gene may contribute to PD susceptibility. In another epigenome-wide association study, conducted to reveal prioritized genes and pathways with statistically significant DNA methylation changes in PD, followed by a subsequent replication analysis of top-ranked CpG sites, single CpG sites of FANCC and TNKS2 showed significant differential methylation between PD cases and controls (Moore et al., 2014). In total, 20 unique genes were identified with a sizable difference in DNA methylation.

Despite the lack of conclusive evidence for the involvement of DNA methylation in the epigenetic regulation of many PD-associated genes, the search for other PD-associated genes and their DNA methylation status is ongoing. Undoubtedly, the significance and consistency of results of genomic DNA methylation in promoter regions of blood samples in comparison with brain samples need to be tested further. Unfortunately, findings from studies searching for PD-specific DNA methylation signatures at the SNCA gene and other PD-associated genes are still inconsistent concerning the clinical significance and specificity of DNA methylation changes in PD. Most importantly, experimental evidence that directly links DNA methylation changes in PD to the deregulation of these genes is still missing. Thus, the importance of differential DNA methylation for molecular mechanisms contributing to the development of PD remains to be investigated in future studies.

Currently, there is a plethora of methods used for measuring DNA methylation (Kurdyukov and Bullock, 2016). To date the “gold standard” for the quantification of DNA methylation is still considered to be bisulfite sequencing. Nowadays this method is often used for genome-wide studies in combination with next-generation sequencing. However, the generation of bisulfite-converted DNA, and its subsequent use has often been described as technically challenging. Additionally, bisulfite conversion can lead to DNA fragmentation and can make amplification of long DNA regions difficult while resulting in chimeric products (Kurdyukov and Bullock, 2016). An easier method is needed that does not require bisulfite conversion, for example, an endonuclease digestion-based assay (historically the first technique utilized for studying DNA methylation), which can be applied at gene-specific loci, but is also compatible with whole genome methylation profiling. Determining a standardized method for quantifying DNA methylation at the same genomic regions of reported PD-associated genes would be ideal for clinical research. Another issue is finding a method that can efficiently detect 5hmC and distinguish it from 5mC, not only on a genome-wide level, but also at bp resolution. Techniques applied to analyze DNA methylation changes associated with PD have mostly not discriminated between 5mC and 5hmC. Particularly in the brain, it will be of great interest to unravel whether the latter DNA methylation mark exhibits disease-specific patterns that could serve as biomarkers. A recent study found an approximate two-fold increase of global DNA hydroxymethylation in the cerebellum of PD patients (Stöger et al., 2017). As this analysis lacks information about where these changes take place in the genome, further experiments will need to shed light on the cause, and examine whether elevated 5hmC levels contribute to PD onset or progression or PD is the reason for the aberrant hydroxymethylation. Approaches that can specifically detect 5hmC have been described, e.g., antibody-based techniques or oxidative bisulfite sequencing (Booth et al., 2012; Skvortsova et al., 2017). These efforts make it likely that methods that discriminate between 5mC and 5hmC will be on hand in the future.

For now, more epigenetic studies are required, particularly ones conducted in different populations, to expand the currently available database of DNA methylation in PD-associated genes. Importantly, a more accurate consensus needs to be reached on the benefit of peripheral blood samples versus brain samples. For the DNA methylation status of a specific gene promoter, such as SNCA or other PD-associated genes to be authenticated as a reliable biomarker of PD status, a significant number of studies reporting consistent results will be needed. In this context, careful analysis of Levodopa treatment effects on SNCA DNA methylation offers the prospect that in the not-so-distant future a reliable DNA methylation biomarker in PD with high sensitivity and specificity will be available (Schmitt et al., 2015). With the growing interest in research on the interdependency between nutrition and epigenetics, in the future we will get a better understanding of what effects nutritional factors have on DNA methylation and what their involvement is in diseases like PD.

Epigenetic modifications may prove to be the missing link between environmental risk factors and the development of PD. Epigenetic variances between individuals could help us to explain the striking clinical differences observed in the age of onset and progression of sporadic PD, and may open the way for rational therapeutic intervention targeting DNA methylation modifications associated with this disorder.

EM-M, KM, AS-C, JS-P, PV-C, and OA-C wrote the manuscript.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.